Identifying traits in migraine attacks to predict treatment response
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
This study is trying to find out if certain features of migraine attacks can help predict how well people will respond to the medication sumatriptan.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 108 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute Academic / other |
| Locations | 1 site (Barcelona) |
| Trial ID | NCT06503848 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify characteristics of spontaneous migraine attacks that may predict how well patients respond to treatment with sumatriptan. Participants will document their headache features and symptoms before and after taking sumatriptan during four migraine episodes. By analyzing the differences between responders and non-responders, the study seeks to enhance personalized treatment approaches for migraine sufferers. The findings could help address the unmet need for effective acute migraine treatments.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with migraine with or without aura who experience fewer than eight migraine days per month.
Not a fit: Patients currently on preventive migraine treatments or those with contraindications to triptans may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients suffering from migraines.
How similar studies have performed: While there is ongoing research into migraine treatments, this specific approach focusing on identifying response predictors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Migraine with or without aura diagnosis according to ICHD-3 criteria * \<8 migraine days per month * Be able to read, write and understand instructions. * Have internet access and mail address * Signing of the informed consent Exclusion Criteria: * Active preventive treatment for migraine * Active medication with an effect over the central nervous system * Serious physical or psychiatric condition * Cardiovascular or hepatic disease * Pregnant or breastfeeding women * Any triptan contraindication * Severe migraine attacks without previous response to triptans or NSAIDs
Where this trial is running
Barcelona
- Hospital Universitari Vall d'Hebron — Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Marta Torres-Ferrús, PhD — Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group
- Study coordinator: Marta Torres-Ferrús, PhD
- Email: cefalea@vhir.org
- Phone: (+34)934893000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.